Jiu-wei-zhen-xiao Granule for Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2021-03-30
Target enrollment:
Participant gender:
Summary
This is a piolt single-arm trial of Jiu-wei-zhen-xiao Granule, extracted from nine kinds of
Chinese medicnie, for the treatment in patients with advanced, unresectable hepatocellular
carcinoma(HCC). The primary objective is to assess its therapeutic efficacy in patients with
unresectable HCC. The primary endpoint is overall survival (OS) after the use of 12-week
drug. Secondary endpoints include progression-free survival (PFS) after the use of 12-week
drug, the improvement of the score of the European Organization for Reasearch and Treatment
of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30), the changes of the liver
function, coagulation function, the size of solid tumors,"Du-tan-yu-jie Zheng" in Chinese
medicine, pain Visual Analogue Scale and toxicity profile of Jiu-wei-zhen-xiao Granule.